Equillium (EQ) Cash from Investing Activities (2018 - 2026)
Equillium (EQ) reported Cash from Investing Activities of -$3000.0 for Q1 2026, down 100.07% year-over-year from $4.5 million in Q1 2025, and up 90.62% quarter-over-quarter from -$32000.0 in Q4 2025.
Equillium (EQ) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Equillium (EQ) has 9 years of Cash from Investing Activities data on file, last reported at -$3000.0 in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$3000.0, down 100.07% year-over-year; the trailing twelve-month figure through Mar 2026 was -$35000.0 (down 100.17% YoY), and the FY2025 annual result was $4.5 million, down 67.68% from the prior year.
- Cash from Investing Activities advanced to -$3000.0 in Q1 2026 per EQ's latest filing, from -$32000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $15.0 million in Q3 2022 and troughed at -$25.2 million in Q1 2023.
- A 5-year average of $2.1 million and a median of $4.5 million in 2025 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities slumped 346.6% in 2022, then surged 258.81% in 2025.
- A 5-year view of Cash from Investing Activities shows it stood at $7.0 million in 2022, then tumbled by 179.76% to -$5.6 million in 2023, then soared by 207.73% to $6.0 million in 2024, then slumped by 100.53% to -$32000.0 in 2025, then jumped by 90.62% to -$3000.0 in 2026.
- Business Quant data shows EQ's Cash from Investing Activities at -$3000.0 in Q1 2026, -$32000.0 in Q4 2025, and $4.5 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Equillium | 293.17 Mn | 232.78 Mn | - | -3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,000.00 |
| Mar 31, 2026 | -3,000.00 |
| Dec 31, 2025 | -32,000.00 |
| Dec 31, 2025 | -32,000.00 |
| Mar 31, 2025 | 4.50 Mn |
| Mar 31, 2025 | 4.50 Mn |
| Dec 31, 2024 | 6.00 Mn |
| Dec 31, 2024 | 6.00 Mn |
| Sep 30, 2024 | 12.00 Mn |
| Sep 30, 2024 | 12.00 Mn |
| Jun 30, 2024 | -1.35 Mn |
| Jun 30, 2024 | -1.35 Mn |
| Mar 31, 2024 | -2.83 Mn |
| Mar 31, 2024 | -2.83 Mn |
| Dec 31, 2023 | -5.57 Mn |
| Dec 31, 2023 | -5.57 Mn |
| Sep 30, 2023 | 10.99 Mn |
| Sep 30, 2023 | 10.99 Mn |
| Jun 30, 2023 | 15.00 Mn |
| Jun 30, 2023 | 15.00 Mn |